Compare · FNA vs WST
FNA vs WST
Side-by-side comparison of Paragon 28 Inc. (FNA) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FNA and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $24.89B, about 22.8x FNA ($1.09B).
- WST has hit the wire 5 times in the past 4 weeks while FNA has been quiet.
- WST has more recent analyst coverage (18 ratings vs 12 for FNA).
- Company
- Paragon 28 Inc.
- West Pharmaceutical Services Inc.
- Price
- $13.10+0.15%
- $359.44+1.96%
- Market cap
- $1.09B
- $24.89B
- 1M return
- -
- +9.61%
- 1Y return
- -
- +71.05%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 5
- Recent ratings
- 12
- 18
Paragon 28 Inc.
Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, such as gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback ankle fusion plating systems. The company also provides precision guide technology for various procedures consisting of MTP fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; total talus spacers to replace the talus and bone in the ankle that connects the leg and foot; bunion or hallux valgus correction systems; phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics, such as bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Further, the company provides hammertoe implants, titanium wedges, and soft tissue fixators, as well as products for the various procedure, such as bunions, flatfoot, fracture fixation, and foot fracture. It serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was incorporated in 2010 and is headquartered in Englewood, Colorado.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest FNA
- Officer Dacosta Albert returned 11,753,724 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Wright Kristina returned 32,118 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Commercial Officer Jarboe Matthew returned 575,320 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Oesterle Stephen N. returned 40,216 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Blackford Quentin S. returned 50,554 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Scanlon Meghan returned 42,113 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Officer Mccormack Robert S returned 203,134 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Officer Chahine Chadi returned 520,657 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Demski David M returned 74,307 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Johnson B Kristine returned 47,347 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest WST
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits